Efficacy and Safety of Immune Checkpoint Inhibitor in Advanced Esophageal Squamous Cell Carcinoma: A Meta-Analysis.

Front Oncol · 2021 · PMC8724211 · PMID 34993139

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The randomized phase 3 trial KEYNOTE-181 ( 13 ) reported that patients with ESCC treated with anti-PD-L1 antibody therapy showed a trend toward longer survival compared with the overall population of patients with ESCC but did not make a direct comparison.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.